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treatment; 10 of these had disease progression. Two 
patients (13 %) were taken off study due to severe toxic-
ity, and one patient (6 %) died from non-treatment-related 
liver failure. One patient had SD for 16 months, receiving 
11 cycles of therapy before being taken off study. The most 
common grade 3 treatment-related toxicities included vom-
iting (n = 2), thrombocytopenia (n = 2), nausea (n = 1), 
and anemia (n = 1). The median PFS was 1.9 months, and 
median OS was 13.1 months.
Conclusion The combination of TMZ and ABT-888 is 
well tolerated in patients with advanced HCC. However, 
the regimen failed to show survival benefit.
ClinicalTrials.gov Identifier NCT01205828.
Keywords Refractory · Hepatocellular carcinoma · 
Temozolomide · Veliparib
Introduction
HCC is known as one of the most lethal human cancer 
types, mostly due to its resistance to chemotherapy and 
radiation. It is the second most common cause of cancer 
death in men and the sixth most common in women world-
wide; this is largely due to the fact that only 30–40 % of the 
patients are amenable to curative treatment at diagnosis [1]. 
Curative treatments include liver resection, transplant, or 
local ablation. Five-year survival for well-selected patients 
who undergo curative therapy is 60–70 % [2]. However, 
most patients are not eligible for curative treatment and 
have a dismal prognosis. Sorafenib (Nexavar, Bayer/Onyx), 
a multi-targeted orally active small molecule tyrosine 
kinase inhibitor, is the first systemic therapy that has shown 
survival benefit in patients with HCC, prolonging PFS 
and OS by 2–3 months. However, the sorafenib response 
Abstract 
Purpose To determine the antitumor efficacy and toler-
ability of combination temozolomide (TMZ) and veliparib 
(ABT-888) in patients with advanced, sorafenib-refractory 
hepatocellular carcinoma (HCC).
Methods This single-arm phase II trial enrolled patients 
with pathologically confirmed, sorafenib-refractory HCC. 
All patients received 40 mg ABT-888 PO daily on days 1–7 
and 150 mg/m2 TMZ PO daily on days 1–5 of a 28-day 
cycle. The primary endpoint was objective response rate 
(ORR) at 2 months. Secondary endpoints included overall 
survival (OS), progression-free survival (PFS), and toxic-
ity profile. Tumor response was assessed every 2 cycles 
using RECIST criteria, and toxicities were assessed using 
CTCAE v4.03.
Results We enrolled 16 patients in the first phase of the 
trial, but the study was discontinued due to a poor ORR; 
only four patients (25 %) had SD after 2 cycles. Twelve 
patients (75 %) were taken off study after 2 months of 
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rate is less than 5 % [3, 4]. Due to the aggressive nature 
of HCC, patients with unresectable disease have a median 
survival of approximately 6–20 months following diag-
nosis [5]. Although locoregional therapies such as trans-
arterial chemoembolization (TACE) and radiofrequency 
ablation (RFA) may improve outcomes [6, 7], HCC shows 
resistance to conventional chemotherapy. Thus, there is an 
urgent need for improved treatment options. One mecha-
nism of tumor resistance to cytotoxic therapy is via repair 
of damaged DNA, and we attempted to overcome this form 
of tumor resistance by targeting tumor DNA repair path-
ways, namely those involving poly(ADP-ribose)-polymer-
ase (PARP) 1 and 2.
DNA-damaging treatments such as cytotoxic chemo-
therapy are still a treatment mainstay for many patients 
with cancer. PARP-1 and PARP-2 are nuclear enzymes that 
become activated in response to DNA damage and facilitate 
DNA repair [8, 9]. Thus, PARP inhibition will result in less 
efficient DNA repair following a cytotoxic insult. As cancer 
cells are genetically unstable, often exhibiting complex kar-
yotypes that include large deletions, insertions, and unbal-
anced translocations of chromosomal material, these cells 
are more susceptible than normal tissues to DNA damage-
induced cytotoxicity [10, 11]. Deficiencies in mismatch 
repair and homologous recombination processes are associ-
ated with the largest number of malignancies. These defi-
ciencies render cells more dependent on PARP for DNA 
repair and hence more sensitive to PARP inhibition [12]. 
PARP-enabled DNA repair may also compensate for the 
loss of other repair pathways. Thus, significantly increased 
poly-ADP-ribosylation and PARP expression was found in 
HCC samples compared with adjacent normal liver tissue 
from the same patient following surgical excision and anal-
ysis [13]. Higher expression of PARP in cancer cells com-
pared with normal cells has been linked to drug resistance 
and the overall ability of cancer cells to sustain genotoxic 
stress [14–17].
ABT-888 is an orally bioavailable PARP-1/2 inhibitor 
that possesses an excellent efficacy and pharmacokinetic 
profile. ABT-888 has been shown to enhance the antitumor 
activity of DNA-damaging agents such as temozolomide, 
irinotecan, cyclophosphamide, and cisplatin [18], and there 
is great potential for the broad use of ABT-888 in combina-
tion with a host of chemo- and radiotherapeutic regimens, 
making it an attractive agent for clinical development.
TMZ is a well-studied DNA-methylating agent that 
crosses the blood–brain barrier and is licensed for the treat-
ment of gliomas and frequently used off-label for malig-
nant melanoma and HCC [19]. TMZ is an oral agent with 
a broad spectrum of antitumor activity and relatively low 
levels of toxicity. In this study, we present the first phase 
II trial utilizing the combination of TMZ and ABT-888 in 
the treatment of advanced, non-transplantable, sorafenib-
refractory HCC.
Materials and methods
Patients and clinical study design
This was an open-label single-arm phase II trial using 
TMZ and ABT-888 as second-line treatment in patients 
with advanced sorafenib-refractory HCC (IRB# 2009-268). 
Patients enrolled in this study received ABT-888 PO 40 mg 
daily on days 1–7 and temozolomide PO 150 mg/m2 daily 
on days 1–5 in 28-day cycles. The trial followed a modi-
fication of Simon’s two-stage optimal design as imple-
mented by Hanfelt et al. [20]. For the first stage, 16 patients 
were accrued. If only 0 or 1 of the 16 patients demonstrated 
disease control during treatment, the treatment would be 
rejected and the trial stopped. However, if at least 2 patients 
(13 %) responded to treatment in the first stage, then an 
additional 33 patients would be recruited to enter into the 
second stage, for a total of 49 patients in this phase II study.
Eligible patients had to be at least 18 years old, have his-
tologically and cytologically confirmed, radiographically 
measurable hepatocellular carcinoma, and have demon-
strated disease progression on first-line sorafenib therapy. 
Progression on sorafenib was defined as radiological or 
clinical progression or documented unacceptable toxicity. 
Patients also had to be Child-Pugh class A or B and have an 
Eastern Cooperative Oncology Group (ECOG) performance 
status score of 0–2 [21]. Other inclusion criteria included 
adequate bone marrow (absolute neutrophil count ≥1500/
mm3; and platelets ≥75,000/mm3), liver function (aspar-
tate transaminase and alanine transaminase ≤3.0 times the 
upper limit of normal range unless liver metastases are pre-
sent, in which case ≤5.0 times the upper limit of normal 
range), and renal function (creatinine clearance ≥30 ml/min 
as calculated by the Cockroft-Gault Equation). Exclusion 
criteria included prior TMZ or PARP inhibitor (ABT-888 or 
other) treatment, anticipation of major surgery during study, 
or concurrent malignancy other than HCC.
Within 30 days of enrollment, each patient received an 
initial clinical evaluation; had laboratory tests performed; 
and underwent a CT scan of the chest, abdomen, and pel-
vis, as well as an MRI of the liver. During treatment, 
patient status was monitored by a complete blood count 
every 2 weeks for the first two cycles and every 4 weeks 
thereafter; a complete metabolic panel with serum alpha-
fetoprotein (AFP) measured every 4 weeks; clinical evalu-
ation every 2 weeks for first two cycles and every 4 weeks; 
and radiological imaging every two cycles unless oth-
erwise indicated. Tumor response and progression were 
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determined according to the Response Evaluation Criteria 
in Solid Tumors (RECIST) [22]. Toxicity was assessed 
at every visit using Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.03. Patients were dis-
continued from the study in the event of disease progres-
sion, uncontrolled side effects, loss to follow-up, or with-
drawal of consent. The MedStar/Georgetown Institutional 
Review Board approved the ethical, legal, and social impli-
cations of the study.
Statistical analysis
The primary objective of this single-arm phase II study 
was to assess the efficacy of ABT-888 and TMZ as a neo-
adjuvant therapy in HCC in terms of ORR after 2 months 
of treatment; this was defined as the combined percent-
age of patients who had CR, PR, and SD. Secondary 
endpoints included OS (defined as the number of months 
between a patient’s enrollment and his/her date of death), 
PFS (defined as the number of months between a patient’s 
enrollment and his/her radiographically confirmed disease 
progression or death), the toxicity profile, and correla-
tions between biological markers and tumor response to 
the combination therapy. Kaplan–Meier methodology was 
used to analyze PFS and OS, which were reported with a 
95 % confidence interval (CI). The log-rank test was used 
to assess the association between clinical factors and sur-
vival. A P value <0.05 was considered statistically signifi-
cant. SAS software version 9.3 (SAS Inc. Cary, N.C.) was 
used for statistical analysis.
Results
Patient characteristics
Between October 2010 and September 2013, 16 patients 
were accrued to this study. The stable disease status that 
was needed to continue enrollment past the first phase 
was achieved in 4 of the 16 patients (25 %), who experi-
enced stable disease after two cycles of treatment. How-
ever, due to the poor ORR (CR + PR + SD) observed, 
accrual to the study was stopped. The demographic and 
baseline characteristics of the enrolled cohort are shown in 
Table 1. The median age was 62 (range, 40–76), and the 
patient group was predominately male (88 %). At baseline 
visit, all patients had an ECOG performance status of 0 or 
1. Eleven patients (69 %) had vascular invasion of their 
tumor, 10 patients (63 %) had liver cirrhosis, and seven 
patients (44 %) had tumor thrombosis. Common etiologies 
of HCC included eight patients (50 %) with viral hepatitis 
C and five patients (32 %) with viral hepatitis B infection. 
Patients were also stratified by most recent serum AFP: 
Seven patients (44 %) had high serum AFP (≥500) and 
nine patients (56 %) had low AFP (<500).
Toxicity
Most patients participating in the trial tolerated the com-
bination therapy well, with most toxicities confined to 
grade 1 or 2 events (Table 2). The most common grade 1 
or 2 adverse events were fatigue (50 %), thrombocytopenia 
(25 %), and nausea (19 %). Five patients (31 %) developed 
grade 3 or 4 adverse events: two counts of thrombocyto-
penia, two counts of severe vomiting, and one count each 
of liver failure, peritoneal bleed, fatigue, nausea, and neu-
tropenia (Table 2). None of the enrolled patients died of 
treatment-related toxicities.
Tumor response
Tumor response to treatment was assessed using CT imag-
ing every 2 cycles of treatment (8 weeks). The median 
number of treatment cycles given to patients enrolled in 
Table 1  Demographics and baseline characteristics of the HCC 
patient cohort
Characteristic Variables n (%)
Age Media (mix–max) 62 (40–76)
Gender Female 2 (12 %)
Male 14 (88 %)
Ethnicity African American 7 (44 %)
Caucasian 5 (32 %)
Asian 2 (12 %)
Other 2 (12 %)
Risk factor Hepatitis C 8 (50 %)
Hepatitis B 5 (32 %)
Non-alcoholic steatohepatitis 2 (13 %)
Alcoholism 1 (6 %)
Cirrhosis Yes 10 (63 %)
No 6 (37 %)
Child-pugh class A 12 (75 %)
B 4 (25 %)
Vascular invasion Yes 11 (69 %)
No 5 (31 %)
Serum alpha-fetoprotein High (>500) 7 (44 %)
Low (<500) 9 (56 %)
Cellular differentiation Well 5 (31 %)
Moderate 8 (50 %)
Poor 3 (19 %)
Tumor thrombosis Yes 7 (44 %)
No 9 (56 %)
ECOG 0 2 (12 %)
1 14 (88 %)
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the trial was two. Ten patients (63 %) had disease progres-
sion after 2 or fewer cycles of treatment and were taken off 
study after their first follow-up imaging scan. Four patients 
(25 %) had stable disease after 2 cycles of treatment: One 
patient demonstrated stable disease for 11 cycles of treat-
ment (16 months); one patient had stable disease for 6 
cycles (6 months) before being taken off study due to dis-
ease progression; one patient had stable disease for 3 cycles 
(3 months) before being taken off study due to non-treat-
ment-related peritoneal bleeding and tumor rupture; and 
the last patient with stable disease was taken off study after 
4 cycles (4 months) due to disease progression. None of 
the patients in the trial demonstrated a partial or complete 
response based on RECIST criteria. Two patients (13 %) 
were taken off study for severe clinical toxicities prior to 
receiving their first imaging scan—one patient was taken 
off study after 4 days of treatment due to severe nausea, 
vomiting, and a Mallory–Weiss tear, and the other patient 
died after 1 month of treatment due to progressive liver cir-
rhosis and hepatorenal syndrome.
Survival and log‑rank analysis
Median PFS (Fig. 1) and OS (Fig. 2) for the entire cohort 
were 1.9 months (95 % CI 1.8–2.0) and 13.1 months (95 % 
CI 0–32.0), respectively. Patients were stratified by serum 
AFP level, presence of tumor vascular invasion, Child-
Pugh grade, and cellular differentiation to measure their 
association with OS and PFS. Using the log-rank test, we 
found that serum AFP, tumor vascular invasion, Child-Pugh 
grade, and cellular differentiation were not significantly 
associated with either OS or PFS after receiving the combi-
nation therapy (Supplementary Figures 1–8).
Discussion
FDA approval of sorafenib, the first and only targeted agent 
for patients with advanced HCC, was an important step 
forward in the treatment of advanced stage hepatic malig-
nancies. However, sorafenib’s clinical benefit is modest, 
prolonging both PFS and OS by only 2–3 months with 
a response rate of less than 5 % [2, 3]. In addition, most 
patients who receive sorafenib eventually develop progres-
sion of their HCC. Given the absence of effective second-
line therapies for patients who have progressed on sorafenib, 
there is an urgent need to find novel treatment combinations.
Table 2  Adverse events 
classified by CTCAE grade in 
patients receiving combination 
treatment
Adverse clinical event Number of Patients (%)
Grade 1 Grade 2 Grade 3
Fatigue 2 (13) 6 (38) 1 (6)
Nausea 3 (19) 0 (0) 1 (6)
Vomiting 2 (13) 0 (0) 2 (13)
Neutropenia 0 (0) 1 (6) 1 (6)
Thrombocytopenia 1 (6) 3 (19) 2 (13)
Peritoneal bleeding from tumor rupture 0 (0) 0 (0) 1 (6)
Liver/kidney failure from hepatorenal syndrome 0 (0) 0 (0) 1 (6)
Reason for treatment discontinuation Number of patients (%)
Disease progression 13 (81)
Grade 3+ clinical toxicity 2 (13)
Death 1 (6)
Fig. 1  Kaplan–Meier curve for progression-free survival
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This study is the first reported in the literature that evalu-
ates the clinical efficacy of the PARP-1/2 inhibitor, ABT-
888, and DNA-methylating agent, TMZ, in advanced HCC 
patients who had disease progression on prior sorafenib 
treatment. The results of the current study show that ABT-
888 and TMZ were well tolerated in patients, although the 
combination therapy did not demonstrate a survival ben-
efit. The median PFS (1.9 months) and OS (13.1 months) 
observed in this study are comparable to the PFS and OS 
observed in patients receiving best supportive care follow-
ing progression on first-line sorafenib [23]. One patient in 
our study had marked disease control, with no progression 
of his HCC for 16 months during treatment. We reviewed 
the disease course of this patient and found that this patient 
had stable disease for 11 months on sorafenib prior to 
enrollment in the current study. Additionally, this patient 
later enrolled in a phase I trial of a drug with a completely 
different mechanism of action and continued to demon-
strate stable disease for 8 months after discontinuing ABT-
888 and TMZ. The prolonged disease control in this patient 
may reflect the slow progression of his cancer, and may not 
be attributed to a specific treatment regimen. Tissue from 
HCC biopsies was obtained from two of the four patients 
who exhibited disease control and five of the ten patients 
who demonstrated disease progression after 2 cycles of 
treatment. However, due to the small number of patients 
(n = 4) who demonstrated disease control, we chose not to 
proceed with molecular analysis of this tissue but instead to 
bank it for future better informed analyses.
All patients eventually developed resistance or intoler-
able clinical toxicities, particularly if the patient had under-
lying liver cirrhosis. Four patients (25 %) had stable dis-
ease after 2 cycles of treatment, but three of these patients 
would be taken off study due to disease progression or non-
treatment-related clinical toxicities after 4 cycles of treat-
ment. Ten patients (63 %) progressed after 2 cycles of treat-
ment, one patient (6 %) died from non-treatment-related 
liver cirrhosis, and one patient (6 %) was taken off study 
after 1 week of treatment due to severe refractory nausea 
and vomiting.
There are several limitations to the current study that 
must be addressed. Due to the small number of patients 
recruited, our findings regarding survival and the toxic-
ity profile should be regarded as exploratory rather than 
confirmatory.
Since 2007, the antitumor efficacy of ABT-888 has been 
evaluated in 83 clinical trials in a myriad of cancer types, 
including breast, ovarian, colon, rectal, pancreas, and lung 
[24]. These studies have improved our understanding of the 
mechanisms by which cancer cells respond and develop 
resistance to PARP-1 and PARP-2 inhibitors. Several fac-
tors may have contributed to HCC resistance to PARP 
inhibition therapy in the current study, such as increased 
expression of DNA repair enzymes. Previous research has 
indicated enhanced homologous recombination capacity 
and defective base excision repair as important contributors 
to ABT-888 and TMZ chemoresistance [25].
Inhibition of PARP-1 activity by ABT-888 limits the 
cell’s ability to repair single-strand DNA breaks via the 
base excision repair pathway, which leads to accumulation 
of double-strand breaks during DNA replication. How-
ever, malignant cells with intact BRCA1 and BRCA2 uti-
lize the homologous recombination pathway as an error-
free rescue mechanism to repair double-strand breaks and 
retain genomic stability [26]. BRCA-deficient cells are 
unable to take advantage of this pathway, and must rely 
on non-homologous end-joining to repair double-strand 
breaks. This pathway is prone to erroneous DNA repair 
and genomic instability, which leads to cancer cell death 
[26]. Patients receiving the combination therapy who have 
BRCA-intact tumors would be less likely to exhibit tumor 
cytotoxicity due to maintenance of homologous recombi-
nation pathway activity. As a result, PARP-1/2 inhibition 
by ABT-888 would be more effective at sensitizing cells 
to single-strand DNA breaks if patients have BRCA- or 
homologous recombination-deficient cancer.
Unfortunately, the prevalence of BRCA mutations in 
HCC is quite low. From whole-genome sequences of over 
1000 HCC cases entered into the Catalogue of Somatic 
Mutations in Cancer (COSMIC) database, rates of BRCA1 
and BRCA2 mutations were 0.07 and 1.7 %, respectively 
[27]. Thus, it remains a challenge to identify patients with 
BRCA-mutated HCC and test the antitumor efficacy of 
PARP inhibitors such as ABT-888 in these patients. As 
mutations in BRCA1 and BRCA2 may predict response 
to PARP inhibition regardless of cancer type, clinical 
Fig. 2  Kaplan–Meier curve for overall survival
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trials testing the efficacy of PARP inhibitors in cancer with 
BRCA1 or BRCA2 mutations may need to be extended 
to all disease types, including HCC. BRCA1 and BRCA2 
mutation testing is not a part of the treatment paradigm for 
HCC, but the increased use of molecular profiling for solid 
tumors may mitigate the difficulty in identifying candidate 
patients for PARP inhibition therapy.
Patients with advanced HCC may harbor defects in other 
genes involved with the repair of double-stranded DNA 
breaks, such as those involved in the MRE11-RAD50-
NBN1 (MRN) complex [28]. However, no studies have 
demonstrated an association between defects in these genes 
and sensitivity to PARP inhibition.
Due to evident patient selection difficulties, identifying 
additional markers that predict which patients will benefit 
from ABT-888 and TMZ therapy is worthwhile. One can-
didate marker is the expression level of O6-methylguanine 
DNA methyltransferase (MGMT), a DNA repair enzyme 
that plays a crucial role in maintaining genomic stability in 
HCC [29]. This protein is mainly regulated at the epigenetic 
level through CpG island promoter methylation, which in 
turn causes functional silencing of the gene [30]. Studies 
have shown that 50–60 % of HCC tumors are MGMT defi-
cient at the genetic and proteomic level [31]. MGMT meth-
ylation and/or low expression have been correlated with 
response to alkylating agents such as temozolomide and 
dacarbazine. MGMT expression levels have been incorpo-
rated into numerous molecular profiling assays, which may 
help clinicians identify patients with advanced HCC who 
are most like to benefit from ABT-888 and TMZ therapy.
HCC is a highly vascularized tumor that relies on a per-
fuse supply of blood for growth and metastasis. Human 
fibroblasts exposed to hypoxic conditions demonstrated 
compromised repair of double-strand DNA breaks, result-
ing in increased chromosomal instability [32]. It may be 
worthwhile to combine ABT-888 and TMZ with locore-
gional therapies such as TACE or trans-arterial radioem-
bolization (TARE), which physically obstruct the arterial 
blood supply of tumors and potentiate tumor hypoxia.
In conclusion, the combination of TMZ and ABT-888 
is relatively well tolerated in patients with advanced HCC. 
However, the regimen failed to demonstrate clinical activ-
ity in unselected patients. Predictive biomarkers that allow 
selection of patients who will respond to combination ABT-
888 and TMZ should be further investigated in a variety of 
cancer types, including HCC.
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